Navigation Links
Advanced Life Sciences Announces Successful Thorough QT Study of Cethromycin
Date:2/19/2008

randomized, parallel study in which cethromycin, given at a therapeutic dose (300 mg once-daily for 5 days) and supratherapeutic dose (900 mg once daily for 5 days) was compared to placebo and moxifloxacin in 238 healthy adult volunteers. Moxifloxacin is an FDA approved anti-infective therapy that was used as a positive control in this study because it has been previously established to cause an increase in the QT interval.

The placebo-corrected QTc mean change from baseline (using the individual correction method for heart rate, or QTcI) for the therapeutic and supratherapeutic doses of cethromycin were -0.4 and 0.9 milliseconds, respectively. Moxifloxacin demonstrated QT prolongation of 4.9 milliseconds, which is consistent with previous clinical experience and thus validated the outcome of the study. In addition to the values for the mean QTcI interval, none of the subjects in the cethromycin cohorts showed increases in the QTcI of greater than 60 milliseconds, nor did any of the cethromycin subjects display a QTcI that exceeded 480 milliseconds at any time.

There were no deaths or serious adverse events reported in the trial in either of the cethromycin cohorts. No hepatic-related adverse events were reported for cethromycin subjects and liver function tests at the therapeutic and supratherapeutic doses were consistent with those observed in prior clinical trials with cethromycin. The most common adverse events reported among cethromycin subjects were gastrointestinal and mild-to-moderate in nature and were consistent with rates reported in prior cethromycin clinical studies at the 300 mg dose level.

Cethromycin is not approved as a treatment for CAP, and data from this analysis have not been reviewed by the FDA.

Cethromycin NDA/Regulatory Calendar:

The Company remains confident in its regulatory strategy for cethromycin in the CAP indication. To gain further insight into the evolving regulatory landscape for antibiotic drug de
'/>"/>

SOURCE Advanced Life Sciences Holdings, Inc.
Copyright©2008 PR Newswire.
All rights reserved

Page: 1 2 3 4 5 6

Related medicine technology :

1. Dendreon Announces Publication of Phase 1 Study Highlighting Immunologic and Clinical Activity of Lapuleucel-T (Neuvenge(R)) in Advanced Breast Cancer Patients
2. Baxter Awarded Pandemic Advanced Supply Contract from the Department of Health
3. Callisto Pharmaceuticals Opens Additional Sites for Phase II Clinical Trial of Atiprimod in Advanced Carcinoid Cancer Patients
4. Genta Initiates Phase 3 AGENDA Trial of Genasense(R) for Patients with Advanced Melanoma
5. Advanced Life Sciences Collaborates with U.S. Government to Study Cethromycin as Treatment for Anthrax and Other High-Priority Biodefense Agents
6. Advanced Life Sciences Announces ALS-357 Granted FDA Orphan Drug Designation for Metastatic Melanoma
7. Advanced Life Sciences to Present Data on Selected Cethromycin Therapeutic Studies at the 47th Interscience Conference on Antimicrobial Agents and Chemotherapy
8. ECLIPSE Data on Effects of Otsukas Investigational Novel Treatment, Tolvaptan, on Advanced Heart Failure Patients Hemodynamics and Urine Output Featured in Heart Failure Society of Americas Late Breaking Trials
9. Newly Published Phase II Study Shows the Investigational Drug Vandetanib Prolongs Progression-Free Survival in Patients with Advanced Non-Small Cell Lung Cancer (NSCLC)
10. Avastin Achieves Impressive Rate of Curative Surgery in Patients with Advanced Colorectal Cancer
11. Ardea Biosciences Lead MEK Inhibitor, RDEA119, to Enter Human Clinical Trials in Advanced Cancer Patients
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:7/30/2015)...  Today we bring you a special edition of #MedicareMonday on Medicare,s 50 th ... of our Medicare resources and continue highlighting the success of the prescription drug benefit, ... Check out our latest infographics and videos here: http://onphr.ma/1INp9qQ ... ... ...
(Date:7/30/2015)... July 30, 2015 PTC Therapeutics, Inc. (NASDAQ: ... reported financial results for the second quarter ending June ... many fronts across the organization.  We are excited to ... dystrophy clinical trial ever conducted with topline results expected ... Chief Executive Officer, PTC Therapeutics, Inc. "Translarna is now ...
(Date:7/30/2015)... 30, 2015 Eisai Inc. announced today that ... United States , European Union and ... respectively) for eribulin, for the treatment of patients with ... chemotherapy for advanced or metastatic disease. ... pivotal global Phase 3 clinical trial (Study 309), which ...
Breaking Medicine Technology:Happy 50th Anniversary Medicare! 2Happy 50th Anniversary Medicare! 3PTC Therapeutics Reports Second Quarter 2015 Financial Results and Provides Corporate Update 2PTC Therapeutics Reports Second Quarter 2015 Financial Results and Provides Corporate Update 3PTC Therapeutics Reports Second Quarter 2015 Financial Results and Provides Corporate Update 4PTC Therapeutics Reports Second Quarter 2015 Financial Results and Provides Corporate Update 5PTC Therapeutics Reports Second Quarter 2015 Financial Results and Provides Corporate Update 6PTC Therapeutics Reports Second Quarter 2015 Financial Results and Provides Corporate Update 7PTC Therapeutics Reports Second Quarter 2015 Financial Results and Provides Corporate Update 8PTC Therapeutics Reports Second Quarter 2015 Financial Results and Provides Corporate Update 9PTC Therapeutics Reports Second Quarter 2015 Financial Results and Provides Corporate Update 10Eisai Submits Simultaneous Regulatory Applications for Eribulin in Soft Tissue Sarcoma in the United States, European Union and Japan 2Eisai Submits Simultaneous Regulatory Applications for Eribulin in Soft Tissue Sarcoma in the United States, European Union and Japan 3Eisai Submits Simultaneous Regulatory Applications for Eribulin in Soft Tissue Sarcoma in the United States, European Union and Japan 4Eisai Submits Simultaneous Regulatory Applications for Eribulin in Soft Tissue Sarcoma in the United States, European Union and Japan 5
... biopharmaceutical company at the forefront of immunology treatment and research, ... in Washington, D.C. by reinforcing its commitment to improving the ... meeting, a large body of UCB data will highlight the ... severe Crohn,s disease. "ACG is an opportunity for ...
... MILPITAS, Calif., Oct. 28, 2011 LifeScan, Inc., the maker ... with Rite Aid to launch the Rite Track ... of American Diabetes Month, a mobile bus will travel to ... to provide complimentary on-site blood glucose and A1c testing, educational ...
Cached Medicine Technology:UCB Proudly Reinforces Long-Standing Commitment to Patients and Physicians at American College of Gastroenterology 2011 Annual Scientific Meeting 2UCB Proudly Reinforces Long-Standing Commitment to Patients and Physicians at American College of Gastroenterology 2011 Annual Scientific Meeting 3Celebrity Chef Sam Talbot Gets on Board for Diabetes Testing 2Celebrity Chef Sam Talbot Gets on Board for Diabetes Testing 3Celebrity Chef Sam Talbot Gets on Board for Diabetes Testing 4
(Date:7/31/2015)... ... ... Super Bowl 50 will emanate from Levi’s Stadium in Santa Clara, CA on ... Super Bowl. In the two weeks that separate the conference championships and the Super Bowl, ... Bowl game will mark the 50th time it has been held and the festivities will ...
(Date:7/31/2015)... ... July 31, 2015 , ... Precision Aesthetics is New ... It was also the first provider of Exilis non-surgical fat reduction in New ... procedures it has attracted a large International clientele. Many patients travel to New ...
(Date:7/31/2015)... VA (PRWEB) , ... July 31, 2015 , ... ... introduced its new store run by GoodThreads. The store can be accessed by ... and designs, many of which are customizable. The best part: whenever a product ...
(Date:7/31/2015)... ... July 31, 2015 , ... Sculpted Contours Luxury Medical Aesthetics announces the arrival ... Zeltiq Aesthetics released this new applicator in the United States as an upgrade to ... thighs. The original applicator required a 2 hour treatment time. The new ...
(Date:7/31/2015)... ... July 31, 2015 , ... Jacksonville-based drug and ... True North Conference Center. The medical community, social workers, law enforcement, and government ... more aligned in the effort to better understand and combat sex trafficking. Lead ...
Breaking Medicine News(10 mins):Health News:Cheap 2016 Super Bowl Tickets at Levi's Stadium: Ticket Down Slashes Ticket Prices on Super Bowl 50 Tickets in Santa Clara, CA at Levi's Stadium 2Health News:Mesothelioma Organization Launches New Store 2Health News:Mesothelioma Organization Launches New Store 3Health News:Cooler Coolsculpting in Atlanta: Treatments Now Twice As Fast 2Health News:Cooler Coolsculpting in Atlanta: Treatments Now Twice As Fast 3Health News:Lakeview Health Links Sex Trafficking and Addiction in Special Jacksonville Educational Workshop 2Health News:Lakeview Health Links Sex Trafficking and Addiction in Special Jacksonville Educational Workshop 3
... Device "Rewires" Brain, Improves and Restores Balance, Normal Walking , ... ... on, "virtual reality" has a whole new meaning for people with ... walk normally again., , , , ,The GaitAid Virtual Walker, a ...
... spring , , SATURDAY, May 16 (HealthDay News) -- Spring ... them, especially if you have asthma. , Pollen from ... trigger that sufferers must learn to cope with this ... Center at Brigham and Women,s Hospital in Boston. Other ...
... Women Find the Solutions to their Infertility Issues by Bridging the ... ... (PRWEB) May 16, 2009 -- National Fertility Link ... to be pregnant. National Fertility Link helps Infertile couples find the ...
... Dr. Gary L. Gottlieb, President of Brigham and Women,s ... Hill Community College,s 35th commencement exercises, on Saturday, ... proponent of alleviating mental health care disparities, will receive ... his outstanding commitment and service to the College. "Dr. ...
... (the "Company") today announced its operating results for the first ... Our net patient service revenue increased by $6.2 million, ... to $95.0 million from $88.8 million for the comparable period ... or 4.2%, less than the same period in 2008, while ...
... chances of macular degeneration , , FRIDAY, May 15 (HealthDay News) ... your eyes as well as the rest of your body, ... vitamins C and E, zinc, lutein, zeaxanthin, omega-3 fatty acids ... low-glycemic index foods) can lower the risk of developing age-related ...
Cached Medicine News:Health News:New Hope for Walking Normally, Living Better With Cerebral Palsy 2Health News:Know Your Asthma Triggers 2Health News:Fewer Than One Percent of Infertile Couples Who Need Treatment Receive It - Website to Bridge Gap Between Infertile Couples and Fertility Clinics 2Health News:Fewer Than One Percent of Infertile Couples Who Need Treatment Receive It - Website to Bridge Gap Between Infertile Couples and Fertility Clinics 3Health News:Healthcare Leader Dr. Gary Gottlieb Keynotes Commencement 2Health News:LifeCare Holdings, Inc. Announces First Quarter Results 2Health News:LifeCare Holdings, Inc. Announces First Quarter Results 3Health News:LifeCare Holdings, Inc. Announces First Quarter Results 4Health News:LifeCare Holdings, Inc. Announces First Quarter Results 5Health News:LifeCare Holdings, Inc. Announces First Quarter Results 6Health News:LifeCare Holdings, Inc. Announces First Quarter Results 7Health News:LifeCare Holdings, Inc. Announces First Quarter Results 8Health News:LifeCare Holdings, Inc. Announces First Quarter Results 9Health News:LifeCare Holdings, Inc. Announces First Quarter Results 10Health News:Nutrient-Rich Diet Lowers Risk of Age-Related Eye Disease 2
... is a national reference laboratory and a ... development. ARUP offers an extensive test menu ... in clinical and anatomic pathology. Owned by ... include more than half of the nation's ...
... national reference laboratory and a worldwide leader ... offers an extensive test menu of highly ... and anatomic pathology. Owned by the University ... than half of the nation's university teaching ...
... national reference laboratory and a worldwide leader ... offers an extensive test menu of highly ... and anatomic pathology. Owned by the University ... than half of the nation's university teaching ...
... national reference laboratory and a worldwide leader ... offers an extensive test menu of highly ... and anatomic pathology. Owned by the University ... than half of the nation's university teaching ...
Medicine Products: